SCHEMBL1290002

SCHEMBL1290002

Cc1c(-c2ccc(C(N)=O)cc2)ccn2c(=O)c(C(=O)O)cc(C3CC3)c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
KDM1A O60341 4/20 0.34
ALDH1A1 P00352 2/20 0.33
ACVR1 Q04771 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
CAMKK1 Q8N5S9 2/20 0.32
CAMKK2 Q96RR4 2/20 0.32
MKNK1 Q9BUB5 2/20 0.32
MKNK2 Q9HBH9 2/20 0.32
NOTUM Q6P988 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C9 P11712 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
CCNA1 P78396 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1290113 0.93 KDM4E (0.34) ALDH1A1KDM4EGAAPKMCAMKK1
SCHEMBL5435666 0.91 CREBBP (0.34) ALDH1A1KDM4EGAAPKMCAMKK1
SCHEMBL1290228 0.89 KDM4E (0.34) ALDH1A1KDM4EGAAPKMCAMKK1
SCHEMBL1290218 0.89 KDM4E (0.38) ALDH1A1KDM4EGAAPKMCAMKK1
SCHEMBL5420315 0.89 BAZ2B (0.40) BRD4BRD9CAMKK1CAMKK2NOTUM
SCHEMBL1290026 0.88 HSD17B10 (0.38) KDM1AALDH1A1KDM4EGAAPKM
SCHEMBL1290198 0.87 NOTUM (0.36) ALDH1A1KDM4EGAAPKMCAMKK1
SCHEMBL19723726 0.87 KDM4E (0.34) ALDH1A1KDM4EGAAPKMCAMKK1
SCHEMBL1290025 0.87 AURKA (0.38) ALDH1A1KDM4EGAAPKMCAMKK1
SCHEMBL5422888 0.87 KDM4E (0.40) BRD4BRD9KDM1AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150141435-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2015-05-21 US claimed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 US claimed
EP-2621491-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS Evolva SA (CH) 2013-08-07 EP claimed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 WO claimed
EP-3476844-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2019-05-01 EP disclosed
EP-3476844-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2019-05-01 EP disclosed
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2019-04-11 US disclosed
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2019-04-11 US disclosed
US-10155021-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2018-12-18 US disclosed
US-20180296555-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2018-10-18 US disclosed
EP-2621491-B1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEV GAITHERSBURG INC (US) 2018-08-29 EP disclosed
EP-3312176-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2018-04-25 EP disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 US disclosed
EP-2621491-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS Evolva SA (CH) 2013-08-07 EP disclosed
WO-2012104305-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2012-08-09 WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 WO disclosed
US-7223773-B2 4-oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SALO PHARMACEUTICAL CO., LTD. (JP) 2007-05-29 US disclosed
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SATO PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
EP-1437354-A1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETON AS PARTIAL STRUCTURE Sato Pharmaceutical Co. Ltd. (JP) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B BRD4 334/4885BRD9 2041/4885KDM1A 1180/4885
US-10155021-B2 Antimicrobial 4-oxoquinolizines DCAF15, CUL4A, CUL4B BRD4 333/4885BRD9 1732/4885KDM1A 1205/4885
US-20180296555-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B BRD4 1356/4885BRD9 3344/4885KDM1A 822/4885
US-20150141435-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B BRD4 1356/4885BRD9 3344/4885KDM1A 822/4885
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SDHA, IL4I1, BLVRB BRD4 187/4885BRD9 2245/4885KDM1A 220/4885
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B BRD4 1153/4885BRD9 3560/4885KDM1A 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.